8.00-9.00 Registration, coffee
Symposium chairs and sponsors
Ravi Majeti (Stanford University, USA): "Precision Medicine in Human AML"
10.10-10.30 Pamela Becker (City of Hope, USA): "High Throughput Drug Screens in Clinical Trials for Hematologic Malignancies: Correlations with Molecular Data"
10.30-10.50 Philipp Staber (Medical University Vienna, Austria): "How to deliver functional precision medicine to patients with blood cancers"
10.50-11.10 Mika Kontro (HUS; FIMM; University of Helsinki, Finland): "Predictive value of ex vivo sensitivity testing of venetoclax in AML: Interim results from the prospective Venex trial"
11.10-11.20 Alexander Waclawiczek (German Cancer Research Center, Germany): "Flow cytometry-based combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Venetoclax and other BH3-mimetics"
11.40-12.00 Jun Yang (St. Jude Children’s Research Hospital, USA): "Pharmacotypes across the genomic landscape of pediatric ALL"
12.00-12.20 Yana Pikman (Harvard University, USA): "Precision medicine for pediatric acute leukemia"
12.20-12.40 Olli Lohi (Tampere University, Finland): "Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-acute leukemia"
12.40-12.50 Merja Heinäniemi (University of Eastern Finland, Finland): "Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia"
13.30-13.50 Bjørn Tore Gjertsen (University of Bergen, Norway): "Single cell signaling profiling in early response evaluation of myeloid leukemia"
13.50-14.10 Eva Szegezdi (National University of Ireland, Galway, Ireland): "Cell-cell interactome alterations of the marrow microenvironment in acute myeloid leukemia"
14.10-14.30 Lars Bullinger (Charité, Germany): "Big Data for Better Outcomes (BD4DO) – AML leads the way in HARMONY"
14.30-14.40 Joseph Saad (University of Helsinki; FIMM): "Monosomy 7 and del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia"
14:40-15:00 Lawrence Boise (Emory University, USA): "Functional and phenotypic approaches to predict responses to venetoclax in multiple myeloma"
15:00-15.20 Klara Kropivsek (ETH Zürich, Switzerland): "A single-cell functional precision medicine landscape of multiple myeloma"
15.20-15.40 Jan Krönke (Charité, Germany): "Proteogenomics analyses for the identification of resistance mechanisms and therapeutic targets in multiple myeloma"
15.40-15:50 Katie Dunphy (Maynooth University): "Understanding extramedullary multiple myeloma using quantitative proteomics"
16.10-16.30 Sascha Dietrich (Medical University Heidelberg, Germany): "Ex-vivo modelling of drug response in B-cell lymphoma"
16.30-17.00 Tea Pemovska (Medical University Vienna, Austria): "Functional precision medicine of T-cell malignancies"
17.00-17.20 Carsten Niemann (Rigshospitalet, Denmark): "Development and implementation of the CLL-TIM model for infection and treatment need into a clinical trial with direct implementation into an Electronic Health Record system"
17.20-17.30 Petra Nygren (University of Helsinki): "High-throughput evaluation of the potential of cancer drugs to enhance natural killer cell cytotoxicity in hematological malignancies"
17.30-19.00 Poster and networking session
19:00- Dinner and social program
8.00-9.00 Registration, coffee
Anthony Letai (Harvard University, USA): "Personalizing cancer therapy with BH3 profiling"
9.40-10.00 Evren Alici (Karolinska Institutet, Sweden): "Strategies to restore and sustain natural killer cell function in hematological malignancies"
10.00-10.20 Olli Dufva (University of Helsinki, Finland): "Single-cell functional genomics of natural killer cell evasion in blood cancers"
10.20-10.30 Sofia Aakko (Faron Pharmaceuticals): "Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome"
11.00-11.20 Ido Amit (Weizmann Institute, Israel): "Single-cell immunology: past, present and future"
11.20-11.40 Bo Porse (BRIC, University of Copenhagen, Denmark): "Single cell proteomics to assess human hematopoiesis"
11.40-12.00 Janne Lehtiö (Karolinska Institutet, Sweden): "Proteogenomics -Connecting cancer genotype and molecular phenotype for precision medicine"
12.00-12.10 Arjen Gebraad (Tampere University): "Bone Marrow and Adipose Tissue Stem/Stromal Cells as Pericytes Generate Distinct Vascular Phenotypes"
12.50-13.10 Olli Kallioniemi (Karolinska Institutet, Sweden): “Functional and data-driven molecular precision medicine in AML”
13.10-13.30 Janghee Woo (Novartis Institute for Biomedical Research, USA): "“Proteogenomic analysis of the CANTOS Canakinumab in anemia and clonal hematopoiesis”"
13.30-13.50 Ilya Shmulevich (Institute of Systems Biology, USA): "Towards Building the AML Digital Twin"
13.50-14.00 Imre Västrik (Institute for Molecular Medicine Finland – FIMM): "Functional precision medicine data platform"
Moderator: Kimmo Porkka (HUS; University of Helsinki, Finland)
Anthony Letai (Harvard University, USA), Kjetil Taskén (University of Oslo, Norway), Olli Kallioniemi (Karolinska Institutet, Sweden), Nikolaus Krall (Exscientia, U.K.), Celine Pallaud (Novartis, Switzerland), Sara (Suomen Syöpäpotilaat ry - Association of Cancer Patients in Finland).